The consortium ACT for Performance and Groupe Conseil Baastel undertook the Mid-term review of PDP III Fund for the RVO (Netherlands Enterprise Agency).

The Netherlands Enterprise Agency (RVO) selected the consortium ACT for Performance and Groupe Conseil Baastel to conduct the third-round review of the Product Development Partnerships (PDP) Fund for the period 2015-2020. A total of €86.3 million was made available, supporting 6 organizations: (i) Medicines for Malaria Venture (MMV); (ii) International Partnership for Microbicides (IPM); (iii) Drugs for Neglected Diseases initiative (DNDi); (iv) TB alliance; (v) International AIDS Vaccine Initiative (IAVI); and (vi) FIND (diagnostics).

The main objective of this review was to assess the progress made by the PDP’s towards their objectives and whether the PDP III fund is on track to meeting its targets.